AAM congratulates Dr. Tidmarsh on appointment as CDER director
“We look forward to a collaborative partnership with Dr. Tidmarsh and the larger team at CDER to prioritize regulatory efficiency.”
AAM
Medicare drug price negotiation may harm generic and biosimilar development, warns report.
The paper concludes that, although the negotiation program might reduce drug costs initially, it could threaten the long-term sustainability of the generics and biosimilars market, a key driver of lower prescription costs.
Patent thickets and litigation abuses hinder all biosimilars
White paper analyzes problems and solutions to patent abuses.
Groups join the Biosimilars Council and AAM letter of support for interchangeability legislation
39 Groups support the Biosimilar Red Tape Elimination Act.
Mark Ratner joins AAM to lead Government Relations
Ratner will lead AAM’s government relations team across federal and state relations, advocacy, and alliances.
AAM wins legal battle against Minnesota's generic pricing law
A Minnesota law was found by the district court and appeals court to regulate prices in other states unlawfully.
AAM Report: Patent settlements deliver $423 billion in savings
The findings underscore these agreements' vital role in expanding patient access and driving down healthcare costs.
AAM issues comments on Section 232 investigation on pharmaceuticals
“AAM and the generics and biosimilars industry look forward to working with the Commerce Department and the White House to engage constructively on ways to incent more domestic investment in the medicines supply chain,” said John Murphy III, president and CEO.
AAM commends Senate Q1/Q2 bill introduction
Saves more than $800 million over 10 years; brings lower-cost medicines to patients soone
AAM congratulates Dr. Mehmet Oz on confirmation as CMS administrator
“AAM and the Biosimilars Council look forward to working with Dr. Oz and his team at CMS to ensure lower-cost medicines are always available for America’s patients.”
AAM issues statement on FDA job cuts
“Today's staff reductions may undermine the Agency’s ability to approve and ensure the safety of lower-cost generic and biosimilar medicines.”
AAM applauds reintroduction of Q1/Q2 House bill
The legislation by Reps. Dunn and Mullin aims to cut red tape, expedite generic approvals, and save $800 million over a decade.
AAM says Inflation Reduction Act undermines generic and biosimilar competition
The AAM warns that IRA price controls may reduce generics and biosimilars, slowing competition and keeping drug prices high.
Industry organizations react to new tariffs imposed by Trump Administration
President Trump said Monday that he would pause tariffs on Mexico and Canada for a month, but levies on China were still set to take effect on Tuesday.
Keren Haruvi reelected chair of the AAM's board of directors
“It has been an honor to lead our AAM board and I’m excited to continue as chair,” said Keren Haruvi, president of Sandoz North America.
John Murphy named president and CEO of AAM
He most recently served as the chief policy officer at the Biotechnology Innovation Organization, where he led BIO’s legal, policy, and international initiatives for the organization’s healthcare portfolio.